Our 4P Plug & Play PET Phantom equalizer turns a network of PET scanners into a homogeneous source. Thanks to its innovative 68Ge system, it enables quantitative assessment with a reduced error vs other technologies in the market.
diXit Solutions 4P Phantom exploits a patented innovative technology that enables nuclear imaging scanner equalization, quantitative assessment and study comparison across a network of PET scanners. Receive the 4P via carrier, place it in the machine and run the qualification process with the help of our remote-assistance team. When finished, pack it and send it back, without any hassle or extra cost.
Current PET phantoms are based on a
18F system that requires the intervention of dedicated local experts for the site / scanner qualification. This process is
expensive, lenghty and highly prone to issues and mistakes.
Since different scanners give different readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of PET in prospective multi-centre clinical trials and in every-day clinical life.
68Ge phantom proved to be a reliable tool for PET scanner qualification, able to significantly reduce the potential sources of error while increasing the reproducibility of PET derived quantitative parameter measurement. It also proved
to be superior to traditional qualitative assessment in several retrospective or mono-centric prospective reports.
The use of a 68Ge phantom allowed reducing the inter-scanner variability among different scanners by 2.5 times, from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR compared to using the 18F phantom. The CTQ criteria were fulfilled at first round in 100% and 28% of PET scanners with 68Ge and 18F respectively.
Simplifies dramatically the procedure of inter-scanner calibration. Compatible with all type of scanners.
Minimize the statistical error
Versus an usual 18F phantom
Inter-scanner error variability reduced from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR vs 18F phantoms
Higher accuracy for future Q-PET-based clinical trials
Reduced human risk and errors. No manual procedures.